Strong IP protection is key to the sustainable growth of a business. Last Tuesday (14/3), our Vice President Jennifer Che, gave a guest lecture as part of the Entrepreneurship Seminar Series hosted by the Faculty of Science of the University of Hong Kong, and introduced to their students and staff the fundamentals of IP and the key factors that go into a strong IP.



Our Past Events

Recommended Insights

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

21 September 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

23 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right